Haemodynamic Effects of Roxatidine, an H2-receptor Antagonist

Overview

Journal Clin Investig

Specialty General Medicine

Date 1992 Feb 1

PMID 1350935

Citations 3

Authors

A Halabi

A Nokhodian

W Kirch

Affiliations

Soon will be listed here.

Abstract

The haemodynamic effects of roxatidine were investigated in 12 patients with congestive heart failure (New York Heart Association class II) in a placebo-controlled, double-blind, randomized, cross-over study. Impedance and mechanocardiography were determined following successive 7-day treatment periods with placebo and roxatidine 150 mg once daily. Comparison with placebo values showed roxatidine to significantly increase the preejection period (109.7 +/- 2.7 ms versus 117.3 +/- 2.7 ms, 1.5 h after administration). Heart rate and blood pressure remained the same. In contrast to other, newer H2-receptor antagonists, which decrease stroke volume and/or cardiac output, roxatidine did not reduce these parameters but increased the preejection period and the ratio of the preejection period to the left ventricular ejection time, indicating a slight negative influence on cardiac performance.

Citing Articles

Combination of H1 and H2 Histamine Receptor Antagonists: Current Knowledge and Perspectives of a Classic Treatment Strategy.

Kou E, Zhang X, Dong B, Wang B, Zhu Y Life (Basel). 2024; 14(2).

PMID: 38398673 PMC: 10890042. DOI: 10.3390/life14020164.

Histamine receptors in heart failure.

Levick S Heart Fail Rev. 2021; 27(4):1355-1372.

PMID: 34622365 DOI: 10.1007/s10741-021-10166-x.

Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis.

Zhang J, Cai W, Zhang Z, Wang P, Lin X, Feng J Medicine (Baltimore). 2018; 97(15):e0409.

PMID: 29642208 PMC: 5908598. DOI: 10.1097/MD.0000000000010409.

References

Halabi A, Kirch W . Negative chronotropic effects of nizatidine. Gut. 1991; 32(6):630-4. PMC: 1378877. DOI: 10.1136/gut.32.6.630. View

Guo Z, Levi R, Graver L, Robertson D, Gay Jr W . Inotropic effects of histamine in human myocardium: differentiation between positive and negative components. J Cardiovasc Pharmacol. 1984; 6(6):1210-5. View

Baumann G, Felix S, Schrader J, Heidecke C, Riess G, Erhardt W . Cardiac contractile and metabolic effects mediated via the myocardial H2-receptor adenylate cyclase system. Characterization of two new specific H2-receptor agonists, impromidine and dimaprit, in the guinea pig and human myocardium. Res Exp Med (Berl). 1981; 179(1):81-98. DOI: 10.1007/BF01852128. View

Hinrichsen H, Halabi A, Kirch W . Haemodynamic effects of H2-receptor antagonists. Eur J Clin Invest. 1992; 22(1):9-18. DOI: 10.1111/j.1365-2362.1992.tb01929.x. View

Kirch W, Halabi A, Linde M, Santos S, Ohnhaus E . Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology. 1989; 96(6):1388-92. DOI: 10.1016/0016-5085(89)90503-9. View

Bristow M, Ginsburg R, Harrison D . Histamine and the human heart: the other receptor system. Am J Cardiol. 1982; 49(1):249-51. DOI: 10.1016/0002-9149(82)90298-3. View

JOHNSON W, Miller D . Ranitidine and bradycardia. Ann Intern Med. 1988; 108(3):493. DOI: 10.7326/0003-4819-108-3-493. View

DALE H, Laidlaw P . The physiological action of beta-iminazolylethylamine. J Physiol. 1910; 41(5):318-44. PMC: 1512903. DOI: 10.1113/jphysiol.1910.sp001406. View

Kirch W, Halabi A, Hinrichsen H . Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clin Pharmacol Ther. 1992; 51(3):325-33. DOI: 10.1038/clpt.1992.29. View

10.

Lameire N, Rosenkranz B, Brockmeier D . Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure. Scand J Gastroenterol Suppl. 1988; 146:100-10. DOI: 10.3109/00365528809099136. View

11.

Erbel R, Belz G . [A study to the analysis of systolic time intervals (author's transl)]. Z Kardiol. 1977; 66(8):433-5. View

12.

Edmunds A, Godfrey S, TOOLEY M . Cardiac output measured by transthoracic impedance cardiography at rest, during exercise and at various lung volumes. Clin Sci (Lond). 1982; 63(2):107-13. DOI: 10.1042/cs0630107. View

13.

Levi R, Chenouda A, Trzeciakowski J, Guo Z, Aaronson L, Luskind R . Dysrhythmias caused by histamine release in guinea pig and human hearts. Klin Wochenschr. 1982; 60(17):965-71. DOI: 10.1007/BF01716956. View

14.

Shah R . Symptomatic bradycardia in association with H2-receptor antagonists. Lancet. 1982; 2(8307):1108. DOI: 10.1016/s0140-6736(82)90038-1. View

15.

Bertaccini G, Coruzzi G, Poli E, Adami M . Pharmacology of the novel H2 antagonist famotidine: in vitro studies. Agents Actions. 1986; 19(3-4):180-7. DOI: 10.1007/BF01966204. View

16.

WEISSLER A, Harris W, SCHOENFELD C . Systolic time intervals in heart failure in man. Circulation. 1968; 37(2):149-59. DOI: 10.1161/01.cir.37.2.149. View

17.

Dammann H, de Looze S, Bender W, Labs R . Clinical characteristics of roxatidine acetate: a review. Scand J Gastroenterol Suppl. 1988; 146:121-34. DOI: 10.3109/00365528809099138. View

18.

Spodick D, Doi Y, Bishop R, Hashimoto T . Systolic time intervals reconsidered. Reevaluation of the preejection period: absence of relation to heart rate. Am J Cardiol. 1984; 53(11):1667-70. DOI: 10.1016/0002-9149(84)90599-x. View

19.

Hinrichsen H, Halabi A, Kirch W . Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther. 1990; 48(3):302-8. DOI: 10.1038/clpt.1990.153. View

20.

KUBICEK W, KARNEGIS J, Patterson R, Witsoe D, Mattson R . Development and evaluation of an impedance cardiac output system. Aerosp Med. 1966; 37(12):1208-12. View